HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
VNDA
Vanda Pharmaceuticals Inc.
VNDA lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
VNDA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Strong |
VNDA's revenue and balance sheet are currently healthy, but its profitability and cash flow are weak.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
VNDA PE Valuation
VNDA has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
VNDA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
VNDA has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over VNDA on earnings, with more consistent year-over-year improvement.
VNDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.63 | -$3.20 |
| Q2 2026 | -$4.64 | -$3.50 |
| Q1 2026 | -$4.06 | -$3.30 |
| Q4 2025 | -$3.74 | -$3.41 |
| Q3 2025 | -$1.43 | -$1.14 |
| Q2 2025 | -$1.14 | -$0.94 |
| Q1 2025 | -$0.76 | -$0.67 |
| Q4 2024 | -$0.33 | -925% |
VNDA lost $4.63 per share over the past year, a bigger loss than the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over VNDA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over VNDA on profitability, with a higher operating margin.
VNDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $69.8M | +24% |
| Q2 2026 | $50.5M | -3.9% |
| Q1 2026 | $51.7M | +3.4% |
| Q4 2025 | $57.2M | +7.6% |
| Q3 2025 | $56.3M | +18% |
| Q2 2025 | $52.6M | +4.2% |
| Q1 2025 | $50M | +5.4% |
| Q4 2024 | $53.2M | +17% |
VNDA's revenue is growing: $70M last quarter, up 24% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -34% | +22 points |
| Q2 2026 | -126% | -53 points |
| Q1 2026 | -97% | -15 points |
| Q4 2025 | -71% | -51 points |
| Q3 2025 | -56% | -33 points |
| Q2 2025 | -73% | -53 points |
| Q1 2025 | -82% | -63 points |
| Q4 2024 | -19% | -3.7 points |
VNDA's operating margin was −34% last quarter, up 22 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over VNDA on cash generation, producing positive trailing cash flow while its opponent burns cash.
VNDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$28.7M | +$3M |
| Q2 2026 | -$31.3M | -$15.7M |
| Q1 2026 | -$50.4M | -$16.9M |
| Q4 2025 | -$29.5M | -$27.5M |
| Q3 2025 | -$31.8M | -$17M |
| Q2 2025 | -$15.6M | -$8.5M |
| Q1 2025 | -$33.6M | -544% |
| Q4 2024 | -$2M | +$2M |
VNDA has burned cash in eight of the last eight quarters: −$140M over the past year, against −$83M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over VNDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
VNDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +239K shares |
| 1 year | +2.3% | +1.4M shares |
| 3 years | +5% | +2.9M shares |
| 5 years | +6% | +3.4M shares |
| Available history | +10% | +5.6M shares |
VNDA has 60M diluted shares, up 2.3% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
VNDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2023 | -80.1x | Net Cash |
| Q2 2023 | -12.2x | Net Cash |
| Q1 2023 | -18.9x | Net Cash |
| Q4 2022 | -14.9x | Net Cash |
| Q3 2022 | -4.5x | Net Cash |
| Q2 2022 | -3.2x | Net Cash |
| Q1 2022 | -2.5x | Net Cash |
| Q4 2021 | -1.2x | Net Cash |
VNDA has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
VNDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.3 | Neutral |
| Stochastic | 11.2 | Oversold |
VNDA's weekly RSI is 31 (neutral) and its Stochastic is 11 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
VNDA PE vs Healthcare Sector
| Metric | VNDA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
VNDA has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
VNDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.23 | 6.6% below |
| 20 week MA | $4.92 | 20% below |
| 50 week MA | $6.12 | 35% below |
| 100 week MA | $5.37 | 26% below |
| 200 week MA | $5.32 | 26% below |
VNDA is in a downtrend: it's below all five of its weekly moving averages, and 26% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over VNDA on returns for 2026, with the stronger performance.
VNDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.8 | $13.3 | -21% |
| 2021 | $13.3 | $18.0 | +35% |
| 2022 | $18.0 | $6.87 | -62% |
| 2023 | $6.87 | $4.22 | -39% |
| 2024 | $4.22 | $4.81 | +14% |
| 2025 | $4.81 | $7.04 | +46% |
| 2026 YTD | $7.04 | $3.95 | -44% |
VNDA has finished lower in three of the last six years. It's down 44% so far in 2026.